The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being investigated in late-stage clinical trials for the manag...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Immunother Cancer
Main Authors: McNeel, Douglas G., Bander, Neil H., Beer, Tomasz M., Drake, Charles G., Fong, Lawrence, Harrelson, Stacey, Kantoff, Philip W., Madan, Ravi A., Oh, William K., Peace, David J., Petrylak, Daniel P., Porterfield, Hank, Sartor, Oliver, Shore, Neal D., Slovin, Susan F., Stein, Mark N., Vieweg, Johannes, Gulley, James L.
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2016
Assuntos:
Position Article and Guidelines
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5170901/
https://ncbi.nlm.nih.gov/pubmed/28031820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-016-0198-x
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares